curative effect

疗效
  • 文章类型: Journal Article
    通过荟萃分析系统评估针灸治疗阿尔茨海默病(AD)认知障碍的疗效,以期为针刺疗法在AD临床过程中的应用提供循证证据。
    从数据库建立到2022年12月31日,中国生物医学文献数据库(CBM),中国国家知识网(CNKI),VIP数据库,万方数据库,Pubmed,系统检索了Embase和Cochrane图书馆数据库。收集已发表的针灸治疗AD认知障碍的随机对照临床试验(RCTS)。干预组给予单纯针刺或联合其他治疗,与对照组相同;对照组给予西医常规治疗。研究的主要结局指标为受试者的认知功能评估,包括:简单精神状态检查量表(MMSE),日常生活能力量表(ADL)评估,阿尔茨海默病认知功能评估量表(ADAS-Cog),中医证候积分(SDSD),蒙特利尔认知测验(MoCA),次要结局指标为不良反应发生情况。文学筛选,数据提取,纳入文献的质量评价由两名研究人员独立进行,根据Cochrane手册中推荐的偏倚风险评估工具。数据采用RevMan5.3软件进行分析。二分变量由风险比(OR)和95%CI表示,连续性变量由平均差异(MD)和95%CI表示。对于异质性分析,当P>0.1且I2≤50%时,应用固定效应模型。当P≤0.1且I2>50%时,应用随机效应模型。
    共有1,172名符合条件的受试者被纳入18个RCTS,干预组595例,对照组577例。meta分析结果如下:针刺干预组改善MMSE[MD=1.67,95%CI(0.94,2.41),P<0.00001],ADL[MD=-1.18,95%CI(-3.09,0.72),P=0.22],ADAS-Cog[MD=3.31,95%CI(5.84,0.78),P=0.01],SDSD[MD=2.40,95%CI(3.53,1.26),P<0.0001],MoCA[MD=4.80,95%CI(3.74,5.86),P=0.04]均优于对照组。干预组未出现与针刺相关的严重不良反应,不良反应发生率和严重程度均低于对照组,具有统计学意义[OR=0.17,95%CI(0.04,0.67),P=0.01]。
    现有数据表明,针灸疗法在改善阿尔茨海默病患者的认知功能障碍和提高自理能力方面具有一定的优势。然而,由于RCTS的数量和评估针灸疗效的病例较少,以及纳入研究中测量偏差和选择性偏差的可能性,它仍然无法对其有效性进行高强度的演示。进一步大规模,高质量随机,需要双盲对照试验来评估其疗效.
    https://inplasy.com/inplasy-2021-12-0125/,标识符:INPLASY2021120125。
    UNASSIGNED: To systematically evaluate the efficacy of acupuncture in the treatment of cognitive impairment in Alzheimer\'s disease (AD) by meta-analysis, in order to provide evidence-based evidence for the application of acupuncture therapy in the clinical process of AD.
    UNASSIGNED: From the establishment of the database to December 31, 2022, China Biomedical Literature Database (CBM), China National Knowledge Network (CNKI), VIP database, WanFang Database, Pubmed, Embase and Cochrane Library Database were systematically searched. To collect published randomized controlled clinical trials (RCTS) of acupuncture in the treatment of cognitive impairment in AD. The subjects in the intervention group were given acupuncture alone or combined with other treatments the same as the control group; the control group received conventional Western medicine treatment. The main outcome indicators of the study were cognitive function assessment of subjects, including: Simple Mental State Examination Scale (MMSE), Assessment of daily Living Ability Scale (ADL), Alzheimer\'s Disease Cognitive Function Assessment Scale (ADAS-Cog), TCM syndrome score (SDSD), Montreal Cognitive Test (MoCA), Secondary outcome indicators were the occurrence of adverse reactions. Literature screening, data extraction, and quality evaluation of the included literature were performed independently by two researchers, according to bias risk assessment tools recommended in the Cochrane manual. Data were analyzed by RevMan5.3 software. Dichotomous variables were represented by risk ratio (OR) and 95% CI, and continuity variables were represented by mean difference (MD) and 95% CI. For heterogeneity analysis, when P > 0.1 and I 2 ≤ 50%, fixed effect model was applied. When P ≤ 0.1 and I 2 > 50%, the random effects model is applied.
    UNASSIGNED: A total of 1,172 eligible subjects were included in 18 RCTS, including 595 in the intervention group and 577 in the control group. The results of meta-analysis are as follows: acupuncture intervention group improved MMSE [MD = 1.67, 95% CI (0.94, 2.41), P < 0.00001], ADL [MD = -1.18, 95% CI (-3.09, 0.72), P = 0.22], ADAS-Cog [MD = 3.31, 95% CI (5.84, 0.78), P = 0.01], SDSD [MD = 2.40, 95% CI (3.53, 1.26), P < 0.0001], MoCA [MD = 4.80, 95% CI (3.74, 5.86), P = 0.04] were better than the control group. No serious adverse reactions related to acupuncture were observed in the intervention group, and the incidence and severity of adverse reactions were lower than those in the control group, with statistical significance [OR = 0.17, 95% CI (0.04, 0.67), P = 0.01].
    UNASSIGNED: Existing data show that acupuncture therapy has certain advantages in improving cognitive dysfunction and improving self-care ability of patients with Alzheimer\'s disease. However, due to the small number of RCTS and cases evaluating the efficacy of acupuncture, and the possibility of measurement bias and selectivity bias in included studies, it is still unable to conduct high-intensity demonstration on its effectiveness. Further large-scale, high-quality randomized, double-blind controlled trials are needed to evaluate its efficacy.
    UNASSIGNED: https://inplasy.com/inplasy-2021-12-0125/, identifier: INPLASY2021120125.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    本研究旨在系统评估射频热凝(RFT)和经皮球囊压迫(PBC)治疗三叉神经痛(TN)的疗效和并发症。
    使用CNKI系统检索RFT和PBC治疗TN的中英文研究,万方数据,VIP,PubMed,EMBASE,科克伦图书馆,直到2022年12月31日。Further,使用特定的纳入和排除标准对文献进行严格筛选.采用RevMan5.4软件进行数据处理和Meta分析。
    总的来说,纳入了16项研究,共3,326名患者。荟萃分析结果显示,两组在术后即刻有效率方面无显著差异,手术后1个月,和术后3个月(比值比[OR]=0.73,95%置信区间[CI]0.35-1.54,p=0.41;OR=0.41,95%CI0.13-1.32,p=0.13;OR=0.40,95%CI0.10-1.60,p=0.20);但是,手术后12个月,差异有统计学意义(OR=0.27,95%CI0.10-0.75,p=0.01)。值得注意的是,术后睡眠质量指数在术后即刻和术后1个月两组间差异无统计学意义(SMD=-0.01,95%CI-2.47~2.44,p=0.99;SMD=0.14,95%CI-3.95~4.22,p=0.95)。Further,两组术后咀嚼肌力下降和口腔疱疹的发生率差异有统计学意义(OR=0.37;95%CI0.21-0.63,p=0.0003;OR=0.25,95%CI0.10-0.61,p=0.003).此外,随访1年的复发率差异有统计学意义(OR=2.23,95%CI1.03-4.81,p=0.04);随访2年的复发率无统计学差异(OR=1.95,95%CI0.33-11.59,p=0.46).
    在TN的治疗中,RFT和PBC均能取得良好的近期疗效,两种方法的结果之间没有显着差异。与RFT相比,PBC可能导致较低的疼痛评分和复发率在中长期,但是感冒疮的发病率更高,咀嚼肌力量的下降更为明显。
    UNASSIGNED: This study aimed to systematically assess the efficacy and complications of radiofrequency thermocoagulation (RFT) and percutaneous balloon compression (PBC) for treating trigeminal neuralgia (TN).
    UNASSIGNED: Chinese and English studies on RFT and PBC in the treatment of TN were systematically searched using CNKI, Wanfang Data, VIP, PubMed, EMBASE, Cochrane Library, and until December 31, 2022. Further, the literature was strictly screened using specific inclusion and exclusion criteria. The RevMan 5.4 software was used for data processing and meta-analysis.
    UNASSIGNED: Overall, 16 studies with 3,326 patients were included. The results of meta-analysis revealed that no significant difference was present between the two groups in terms of the rate of efficacy immediately after surgery, 1 month after surgery, and 3 months after surgery (odds ratio [OR] = 0.73, 95% confidence interval [CI] 0.35-1.54, p = 0.41; OR = 0.41, 95% CI 0.13-1.32, p = 0.13; OR = 0.40, 95% CI 0.10-1.60, p = 0.20); however, at 12 months after surgery, the difference was statistically significant (OR = 0.27, 95% CI 0.10-0.75, p = 0.01). Notably, there was no significant difference in the postoperative sleep quality index between the two groups immediately after surgery and 1 month after surgery (SMD = -0.01, 95% CI -2.47 to 2.44, p = 0.99; SMD = 0.14, 95% CI -3.95 to 4.22, p = 0.95). Further, statistically significant differences were observed between the two groups in the incidence of postoperative masticatory muscle strength decline and oral herpes (OR = 0.37; 95% CI 0.21-0.63, p = 0.0003; OR = 0.25, 95% CI 0.10-0.61, p = 0.003). In addition, a statistically significant difference was found in the recurrence rate at 1-year follow-up (OR = 2.23, 95% CI 1.03-4.81, p = 0.04); however, no statistically significant differences were found in the recurrence rate at the 2-year follow-up (OR = 1.95, 95% CI 0.33-11.59, p = 0.46).
    UNASSIGNED: In the treatment of TN, both RFT and PBC can achieve good short-term efficacy, and no significant differences were noted between the outcomes of the two approaches. Compared with RFT, PBC may result in a lower pain score and recurrence rate in the medium and long terms, but it is a higher incidence of cold sores, and the decrease of masticatory muscle strength is more obvious.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    药物通常用于治疗偏头痛。然而,患者可能会出现不良事件或对药物治疗无效。近年来,神经调节技术已成为治疗偏头痛的潜在非药物疗法.本文重点对非侵入性迷走神经刺激(n-VNS)治疗偏头痛的随机对照试验进行系统评价和荟萃分析,以确定疗效。n-VNS的安全性和耐受性。
    我们搜索了PUBMED,EMBASE,和CochraneCenter受控试验注册数据库,截至2022年7月15日。主要结果是每月减少偏头痛/头痛天数,和2小时内无痛率。次要结局是≥50%的应答率,头痛强度,每月急性药物减少天数,和不良事件。
    Meta分析显示,非侵入性颈迷走神经刺激(n-cVNS)显着影响≥50%的应答率(OR,1.64;95%CI,1.1至2.47;p=0.02),但对减少偏头痛天数没有显著影响(MD,-0.46;95%CI,-1.21至0.29;p=0.23)和头痛天数(MD,-0.68;95%CI,-1.52至0.16;p=0.11)。相比之下,发现低频非侵入性耳迷走神经刺激(n-aVNS)显着减少偏头痛天数(MD,-1.8;95%CI,-3.34至-0.26;p=0.02)和头痛强度(SMD,-0.7;95%CI,-1.23至-0.17;p=0.009),但不是每月急性用药天数(MD,-1.1;95%CI,-3.84至1.64;p=0.43)。此外,在大多数患者中发现n-cVNS是安全且耐受性良好的。
    这些发现表明,n-VNS是一种有前途的偏头痛管理方法。
    UNASSIGNED: Medication is commonly used to treat migraine. However, patients may experience adverse events or fail to respond to medication. In recent years, neuromodulation techniques have emerged as potential non-pharmacological therapy for migraine. This article focuses on a systematic review and meta-analysis of randomized controlled trials of non-invasive vagus nerve stimulation (n-VNS) for migraine to determine the efficacy, safety and tolerability of n-VNS.
    UNASSIGNED: We searched PUBMED, EMBASE, and Cochrane Center Register of Controlled Trials databases up to July 15, 2022. Primary outcomes were monthly reduced migraine/headache days, and pain-free rates within 2 h. Secondary outcomes were  ≥ 50% responder rate, headache intensity, monthly acute medication reduction days, and adverse events.
    UNASSIGNED: Meta-analysis shows that non-invasive cervical vagus nerve stimulation (n-cVNS) significantly impacted ≥50% responder rate (OR, 1.64; 95% CI, 1.1 to 2.47; p = 0.02), but had no significant effect on reducing migraine days (MD, -0.46; 95% CI, -1.21 to 0.29; p = 0.23) and headache days (MD, -0.68; 95% CI, -1.52 to 0.16; p = 0.11). In contrast, low-frequency non-invasive auricular vagus nerve stimulation (n-aVNS) was found to significantly reduce the number of migraine days (MD, -1.8; 95% CI, -3.34 to -0.26; p = 0.02) and headache intensity (SMD, -0.7; 95% CI, -1.23 to -0.17; p = 0.009), but not the number of acute medication days per month (MD, -1.1; 95% CI, -3.84 to 1.64; p = 0.43). In addition, n-cVNS was found safe and well-tolerated in most patients.
    UNASSIGNED: These findings show that n-VNS is a promising method for migraine management.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    急性心肌梗死(AMI)院前急救是挽救患者的重要途径。然而,院前急救的方式还存在一些争议。因此,本文进行Meta分析,评价不同院前护理对AMI合并左心衰竭的疗效及预后。
    通过在数据库中搜索已发表的研究,筛选出与AMI合并左心衰竭患者院前急救相关的文献.根据纽卡斯尔-渥太华量表(NOS)评价文献质量,提取相应数据进行Meta分析。对7个结局指标(治疗后患者的临床效果,呼吸频率,心率,收缩压(SBP),舒张压(DBP),生存状态,和并发症的发生率)。漏斗图和Egger检验用于测试偏差风险。
    最终共收录了16篇文章,共包括1,465名患者。文献质量评价发现,有8篇文献被评为低偏倚风险,8篇文献被评为中等偏倚风险。荟萃分析结果显示,先救后救组的临床效果优于先救后救组[风险比(RR)=1.35,95%置信区间(CI):1.27至1.45,P<0.01];呼吸频率降低[均差(MD)=-4.84,95%CI:-6.50至-3.18,P<0.01];心率下降(P=95%-P=1.64%,PCI=1.50%=
    院前急救再转运可以显着提高患者的临床治疗效果。然而,考虑到本文纳入的文献均为非随机对照研究,纳入文献的总体质量不高,研究数量有限,需要进一步探索。
    UNASSIGNED: Pre-hospital first aid for acute myocardial infarction (AMI) is an important way to save patients. However, there are still some disputes about the way of pre-hospital first aid. Therefore, this paper provides a Meta-analysis to evaluate the efficacy and prognosis of different prehospital care for AMI with left heart failure.
    UNASSIGNED: By searching the published studies in the databases, the literature related to the pre-hospital first aid for patients with AMI and left heart failure was screened out. The quality of the literature was evaluated according to the Newcastle-Ottawa scale (NOS), and the corresponding data were extracted for meta-analysis. Meta-analysis was performed on 7 outcome indicators (clinical effect of patients after treatment, respiratory rate, heart rate, systolic blood pressure (SBP), diastolic blood pressure (DBP), survival status, and incidence of complications). A funnel plot and Egger\'s test were used to test risk of bias.
    UNASSIGNED: A total of 16 articles were finally included, comprising a total of 1,465 patients. The literature quality evaluation found that 8 literatures were rated as low risk of bias, and 8 literatures were rated as medium risk of bias. The meta-analysis results showed that the clinical effect of the first aid and then transportation group was better than that of the transportation and then first aid group [risk ratio (RR) =1.35, 95% confidence interval (CI): 1.27 to 1.45, P<0.01]; the respiratory rate decreased [mean difference (MD) =-4.84, 95% CI: -6.50 to -3.18, P<0.01]; the heart rate decreased (MD =-11.34, 95% CI: -12.69 to -9.99, P<0.01); SBP decreased (MD =-6.00, 95% CI: -10.00 to -2.00, P<0.01); the DBP decreased (MD =-3.54, 95% CI: -4.45 to -2.64, P<0.01); the survival status of the patients improved (RR =1.29, 95% CI: 1.18 to 1.41, P<0.01); the incidence of complications was reduced (RR =0.31, 95% CI: 0.20 to 0.48, P<0.01).
    UNASSIGNED: Pre-hospital first aid and then transportation can significantly improve the clinical treatment effect of patients. However, considering that the literatures included in this paper are non-randomized controlled studies and the overall quality of the included literatures is not high and the number of studies is limited, further exploration is needed.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    随着老龄化社会的发展趋势,阿尔茨海默病(Alzheimer’sdisease,AD)已成为全球医学领域亟待解决的问题。AD患者的认知障碍导致日常生活能力下降,行为和人格异常,导致异常的精神症状,严重影响患者的日常生活。目前,临床上主要用于AD患者的药物治疗,但是很大一部分患者会经历药物功效不起作用,甚至有些药物会带来严重的睡眠障碍。针灸,以其独特的概念和治疗方法,经大量实验验证,证明了针刺治疗AD的可靠性。针灸治疗AD的神经生物学机制研究取得了许多进展,进一步证明了针灸治疗AD的良好疗效和独特优势。本文首先对AD的发病机制进行综述,然后阐述针灸治疗AD的研究进展,包括针刺对AD体内生化指标变化的影响及发挥治疗作用的具体作用机制。AD相关指标的变化同样进一步验证了针刺治疗的有效性。针灸治疗AD的临床和机理研究正在加强,以适应社会发展的需要。相信随着研究的进展,针灸治疗AD将取得新的成果。
    With the development trend of an aging society, Alzheimer\'s disease (AD) has become an urgent problem in the field of medicine worldwide. Cognitive impairment in AD patients leads to a decline in the ability to perform daily living and abnormalities in behavior and personality, causing abnormal psychiatric symptoms, which seriously affect the daily life of patients. Currently, mainly drug therapy is used for AD patients in the clinic, but a large proportion of patients will experience drug efficacy not working, and even some drugs bring severe sleep disorders. Acupuncture, with its unique concept and treatment method, has been validated through a large number of experiments and proved its reliability of acupuncture in the treatment of AD. Many advances have been made in the study of the neurobiological mechanisms of acupuncture in the treatment of AD, further demonstrating the good efficacy and unique advantages of acupuncture in the treatment of AD. This review first summarizes the pathogenesis of AD and then illustrates the research progress of acupuncture in the treatment of AD, which includes the effect of acupuncture on the changes of biochemical indicators in AD in vivo and the specific mechanism of action to exert the therapeutic effect. Changes in relevant indicators of AD similarly further validate the effectiveness of acupuncture treatment. The clinical and mechanistic studies of acupuncture in the treatment of AD are intensified to fit the need for social development. It is believed that acupuncture will achieve new achievements in the treatment of AD as research progresses.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • DOI:
    文章类型: Journal Article
    目的:系统评价造血干细胞移植(HSCT)和骨髓移植(BMT)治疗急性髓系白血病(AML)的疗效。
    方法:PubMed,EMBASE,ScienceDirect,科克伦图书馆,中国国家知识基础设施(CNKI),中国VIP数据库,检索万方数据库和中国生物医学文献数据库(CBM),寻找骨髓HSCT和外周HSCT(PHSCT)治疗AML的病例对照试验。两名独立研究人员提取了2000年1月至2022年5月之间的数据。根据CochraneHandbook5.3中定义的偏倚风险对检索到的每篇文章进行评估,并使用RevMan5.3通过荟萃分析对数据进行分析。
    结果:通过计算机数据库检索,包括7项临床对照研究,1280个样本对生存率进行荟萃分析。PHSCT组和BMT组的总生存率(OS)和无病生存率(DFS)差异无统计学意义(P>0.05)。BMT组急性移植物抗宿主病(GVHD)和慢性GVHD的发生率明显降低(P<0.05)。BMT组疾病复发率较低(P<0.05),但复发相关死亡率无明显差异(P>0.05)。此外,非复发相关死亡率也无显著差异(P>0.05).漏斗图是根据操作系统速率绘制的,DFS速率,急性GVHD和慢性GVHD的发病率,和复发。之后进行发表偏倚分析。在大多数漏斗图中呈现对称性,在少数图中看到不对称性,由于样本少和异质性,在所选文献中可能存在发表偏倚。
    结论:BMT可作为AML患者的有效治疗方法,因为它可以在确保疗效的同时降低复发率和并发症的发生率,提示BMT值得在临床上推广。需要更长的随访研究,为BMT在AML患者中的临床应用提供更多支持。
    OBJECTIVE: To systematically assess the efficacy of hematopoietic stem cell transplantation (HSCT) and bone marrow transplantation (BMT) in treating acute myeloid leukemia (AML).
    METHODS: PubMed, EMBASE, ScienceDirect, Cochrane Library, China National Knowledge Infrastructure (CNKI), China VIP database, Wanfang database and China Biomedical Literature Database (CBM) were searched for case-control trials of bone marrow HSCT and peripheral HSCT (PHSCT) for treating AML. Two independent researchers extracted the data between January 2000 and May 2022. Each retrieved article was assessed according to the bias risk defined in Cochrane Handbook 5.3, and data were analyzed by meta-analysis using RevMan5.3.
    RESULTS: Through computer database retrieval, 7 clinical controlled studies were included, with 1280 samples. A meta-analysis was conducted on the survival rates. The PHSCT and the BMT groups showed no noticeable difference in overall survival (OS) and disease-free survival (DFS) rates (P>0.05). The incidence of acute graft-versus-host disease (GVHD) and chronic GVHD in the BMT group was noticeably lower (P<0.05). The disease recurrence rate in tthe BMT group was lower (P<0.05), but no noticeable differences were found in recurrence-related mortality (P>0.05). Furthermore, there was also no noticeable difference in non-relapse-related mortality (P>0.05). Funnel charts were drawn on the basis of OS rate, DFS rate, incidences of acute GVHD and chronic GVHD, and recurrence. Afterwards publication bias analysis was carried out. Symmetry presented in the majority of the funnel charts and asymmetry was seen in a few, suggesting possible publication bias in the selected literature because of the small sample and the heterogeneity.
    CONCLUSIONS: BMT can be used as an effective treatment for patients with AML, because it can reduce the recurrence rate and the incidence of complications while ensuring a curative effect, suggesting that BMT is worth popularizing in the clinic. Longer follow-up studies are needed to provide more support for the clinical application of BMT in AML patients.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Meta-Analysis
    背景:目前,治疗后莱姆病(PTLDS)的发病机制尚不清楚,所以PTLDS的治疗方案,尤其是抗生素治疗,仍然有争议。本研究旨在使用网络荟萃分析(NMA)评估抗生素在PTLDS治疗中的疗效。
    方法:遵循PRISMA指南,对PubMed的随机对照试验进行了系统的文献检索,EMBASE,WebofScience和Cochrane图书馆(文献从数据库开始到2022年12月16日)。采用随机效应模型和固定效应模型。采用STATA17.0软件评价纳入研究文献的质量和异质性。
    结果:该系统包括4项随机对照试验(485名受试者)。网络荟萃分析显示,头孢曲松在FSS量表评分中的效果优于安慰剂[Mean=0.87,95%CI(0.02,1.71)]和多西环素[Mean=1.01,95%CI(0.03,1.98)]。其他药物治疗后FSS量表评分无统计学差异。就FSS评分结果而言,根据每种治疗的SUCRA值(97.7),头孢曲松是最佳干预措施。贝克抑郁量表(BDI)等结果指标的分析,心理健康量表和身体功能量表显示,抗生素组和安慰剂组之间没有统计学上的显着差异。
    结论:头孢曲松治疗可能是抗生素治疗PTLD的最佳选择,为未来PTLD的抗生素治疗提供了有益的指导。
    BACKGROUND: At present, the pathogenesis of post-treatment Lyme disease (PTLDS) is not clear, so the treatment scheme of PTLDS, especially antibiotic treatment, is still controversial. This study aims to evaluate the efficacy of antibiotics in the treatment of PTLDS using network meta-analysis (NMA).
    METHODS: Following PRISMA guidelines, a systematic literature search was conducted on randomized controlled trials in PubMed, EMBASE, Web of Science and Cochrane Library (the literature was published from database inception through December 16, 2022). Using random effect model and fixed effect model. STATA17.0 software was used to evaluate the quality and heterogeneity of the included research literature.
    RESULTS: The system included 4 randomized controlled trials (485 subjects). The network meta-analysis showed that ceftriaxone had better results than placebo [Mean = 0.87, 95% CI (0.02, 1.71)] and doxycycline [Mean = 1.01, 95% CI (0.03, 1.98)] in FSS scale scores. There was no statistical difference in FSS scale scores of other drugs after treatment. In terms of FSS score results, Ceftriaxone was the best intervention according to the SUCRA value of each treatment (97.7). The analysis of outcome indicators such as Beck Depression Inventory (BDI), Mental-health Scale and Physical-functioning scale showed that there was no statistically significant difference between the antibiotic group and placebo group.
    CONCLUSIONS: Ceftriaxone treatment may be the best choice for antibiotic treatment of PTLD, which provides useful guidance for antibiotic treatment of PTLD in the future.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Systematic Review
    目的:探讨肺动脉高压(PAH)治疗门脉高压(POPH)的疗效。设计:系统评价和荟萃分析。配景:POPH是终末期肝病的严重并发症,存活率低。肝移植是一种有效的治疗方法。由于POPH的存在,有些患者不能接受LT。PAH治疗后,POPH患者可获得良好的血流动力学和心功能,但是没有标准的指导方针。方法:两名独立研究人员搜索PubMed,EMBASE,科克伦图书馆,和WebofScience从开始到2022年9月27日发表的研究,重点是所有POPH患者的血流动力学和心脏功能的变化,以了解PAH治疗对整个POPH患者人群的影响。其中,我们具体分析了中重度POPH患者血流动力学和心功能的变化.收集相关数据后,使用R程序meta包进行meta分析.结果:共检索到2,775篇文献,包括24篇文献。结果显示,在所有POPH患者(n=1046)中,使用PAH药物后,以下指标显着改善:mPAP:(MD=-9.11mmHg,p<0.0001);PVR:(MD=-239.33dyn·s·cm-5,p<0.0001);CO:(MD=1.71L/min,p<0.0001);心脏指数:(MD=0.87L/(min·m2),p<0.0001);6MWD:(MD=43.41m,p<0.0001)。在中度至重度POPH患者中(n=235),使用PAH药物后,以下指标显着改善:mPAP(MD=-9.63mmHg,p<0.0001);PVR(MD=-259.78dyn·s·cm-5,p<0.0001);CO(MD=1.76L/min,p<0.0001);心脏指数:(MD=1.01L/(min·m2),p=0.0027);6MWD:(MD=61.30m,p<0.0001)。结论:应用PAH药物可改善POPH患者的心肺血流动力学和心功能,尤其是中度至重度POPH患者,上述变化更为积极。系统审查注册:https://inplasy.com,标识符INPLASY202250034。
    Objective: To determine the therapeutic effect of pulmonary arterial hypertension (PAH) agents for portal pulmonary hypertension (POPH). Design: Systematic review and meta-analysis. Background: POPH is a serious complication of end-stage liver disease with a low survival rate. Liver transplantation (LT) is an effective treatment. Due to the presence of POPH, some patients cannot undergo LT. After PAH treatment, patients with POPH can obtain good hemodynamics and cardiac function for LT, but there are no standard guidelines. Methods: Two independent researchers searched PubMed, EMBASE, Cochrane Library, and Web of Science for studies published from inception to 27 September 2022, focusing on the changes in hemodynamics and cardiac function in all patients with POPH to understand the effect of PAH treatment on the entire population of POPH patients. Among these, we specifically analyzed the changes in hemodynamics and cardiac function in moderate and severe POPH patients. After collecting the relevant data, a meta-analysis was carried out using the R program meta-package. Results: A total of 2,775 literatures were retrieved, and 24 literatures were included. The results showed that in all POPH patients (n = 1,046), the following indicators were significantly improved with PAH agents: mPAP: (MD = -9.11 mmHg, p < 0.0001); PVR: (MD = -239.33 dyn·s·cm-5, p < 0.0001); CO: (MD = 1.71 L/min, p < 0.0001); cardiac index: (MD = 0.87 L/(min·m2), p < 0.0001); 6MWD: (MD = 43.41 m, p < 0.0001). In patients with moderate to severe POPH (n = 235), the following indicators improved significantly with PAH agents: mPAP (MD = -9.63 mmHg, p < 0.0001); PVR (MD = -259.78 dyn·s·cm-5, p < 0.0001); CO (MD = 1.76 L/min, p < 0.0001); Cardiac index: (MD = 1.01 L/(min·m2), p = 0.0027); 6MWD: (MD = 61.30 m, p < 0.0001). Conclusion: The application of PAH agents can improve cardiopulmonary hemodynamics and cardiac function in patients with POPH, especially in patients with moderate to severe POPH, and the above changes are more positive. Systematic Review Registration: https://inplasy.com, identifier INPLASY202250034.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    未经批准:目前,儿童隐匿性脊髓栓系综合征(OTCS)的手术治疗主要是两种类型的微创手术:纤维终末松弛或纤维终末切除术。微创治疗和保守治疗的临床疗效和安全性尚不清楚。因此,本研究将利用系统综述和荟萃分析的优势来评价客观性,探讨微创手术治疗小儿隐匿性脊髓栓系综合征的效果。
    未经评估:使用计算机搜索来搜索PubMed,Embase,CNKI,万方数据库和其他文献检索网站关于儿童隐匿性脊髓栓系综合征和脊髓脂肪瘤微创手术的随机对照试验(RCT)。手动搜索专业期刊以避免遗漏。搜索关键词是:隐匿性骨髓脂肪瘤,隐匿性脊髓栓系综合征,脊髓栓系综合征的外科治疗,隐匿性脊髓栓系综合征。
    UNASSIGNED:共选取6篇可用于Meta分析的相关文献。本文共纳入425名受试者,其中132例保守治疗,293例手术治疗。纳入研究的异质性检测检验统计量为Chi2(卡方检验)=8.18,df(自由度)=5,I2=39%<50%,Z=2.53,纳入研究的同质性好。保守治疗未好转病例数40例,占30.30%;手术治疗未好转病例数33例,占11.26%,两组总的未好转率占17.17%。实验组的未好转率明显低于对照组,差异有统计学意义(P=0.01)。偏倚分析结果显示,纳入本研究的文献中不存在显著偏倚。
    UNASSIGNED:荟萃分析结果证实,微创手术对隐匿性脊髓栓系综合征患儿的治疗具有显着效果。然而,由于纳入文献的样本量小,需要进一步评估治疗风险.
    UNASSIGNED: At present, the surgical treatment of occult tethered cord syndrome (OTCS) in children is mostly two types of minimally invasive surgery: filum terminalis laxity or filum terminalectomy. The clinical efficacy and safety of minimally invasive treatment and conservative treatment are still unclear. Therefore, this study will use the advantages of systematic review and meta-analysis to evaluate the objectivity, and explore the effect of minimally invasive surgery on children with occult tethered cord syndrome.
    UNASSIGNED: A computer search was used to search PubMed, Embase, CNKI, Wanfang Database and other literature search websites about the randomized controlled trials (RCTs) of minimally invasive surgery in children with occult tethered cord syndrome and spinal lipoma. Professional journals were manually searched to avoid omissions. The search keywords were: occult myelolipoma, occult tethered cord syndrome, surgical treatment of tethered cord syndrome, occult tethered cord syndrome.
    UNASSIGNED: A total of 6 relevant literatures that could be used for meta-analysis were selected. A total of 425 subjects were included in the article, of which 132 were treated conservatively and 293 were treated surgically. The heterogeneity detection test statistics of the included studies were Chi2 (Chi-squared test) =8.18, df (degree of freedom) =5, I2=39%<50%, Z=2.53, and the homogeneity of the included studies was good. The number of unimproved cases under conservative treatment was 40, accounting for 30.30%; the number of unimproved cases under surgical treatment was 33, accounting for 11.26%, and the total unimproved rate of the two groups accounted for 17.17%. The unimproved rate of the experimental group was significantly lower than that of the control group, and the difference was statistically significant (P=0.01). The results of bias analysis showed that there was no significant bias in the literature included in this study.
    UNASSIGNED: Meta-analysis results confirmed that minimally invasive surgery has a significant effect on the treatment of occult children with tethered cord syndrome. However, due to the small sample size of the included literature, further evaluation of the treatment risk is required.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:可以通过使用沙库巴曲/缬沙坦来减少梗塞(AMI)。然而,沙库必曲/缬沙坦在临床治疗中的疗效不一致.在本文中,全面搜索了沙库巴曲/缬沙坦在AMI中应用的相关研究,探讨AMI后早期应用沙库巴曲/缬沙坦的临床疗效及安全性。
    方法:英文数据库,包括美国国家医学图书馆,Medline,和Embase,和中国数据库,包括中国生物医学文献数据库,中国国家知识基础设施(CNKI),万方,VIP,使用以下搜索词的组合进行搜索:AMI,急性ST段抬高型心肌梗死(STEMI),急性非ST段抬高型心肌梗死(NSTEMI),沙库巴曲/缬沙坦钠片,和血管紧张素受体脑啡肽酶抑制剂。实验组给予沙巴曲/缬沙坦钠片,对照组给予血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂(ACEI/ARB)。采用CochraneHandbook5.0风险评估表进行质量评估和偏倚风险评估。
    结果:共有5篇文献纳入荟萃分析。沙库巴曲/缬沙坦组心血管不良事件总发生率明显低于对照组{相对危险度(RR)=0.61[95%可信区间(CI):0.46,0.82],显著性检验Z=3.36,P=0.0008}。沙库巴曲/缬沙坦组与对照组的再住院率差异有统计学意义[RR=0.67(95%CI:0.47,0.95),显著性检验Z=2.23,P=0.03]。沙库必曲/缬沙坦组与对照组之间的低血压差异有统计学意义[RR=1.28(95%CI:1.18,1.40),显著性检验Z=5.58,P<0.00001]。沙库必曲/缬沙坦组与对照组的左心室射血分数(LVEF)差异有统计学意义[平均差异(MD)=3.09(95%CI:1.69,4.49),显著性检验Z=4.33,P<0.0001]。
    结论:发现舒必曲/缬沙坦抑制AMI后心室重构,改善心脏功能,降低心肌梗死后不良心血管事件的发生率,再住院率,和死亡率。
    BACKGROUND: infarction (AMI) can be reduced by the use of sacubitril/valsartan. However, the therapeutic effects of sacubitril/valsartan in clinical settings are inconsistent. In this paper, the related research on the application of sacubitril/valsartan in AMI was comprehensively searched, in order to explore the clinical efficacy and safety of early application of sacubitril/valsartan after AMI.
    METHODS: English databases, including American National Library of Medicine, Medline, and Embase, and Chinese databases, including Chinese Biomedical Literature Database, Chinese National Knowledge Infrastructure (CNKI), Wanfang, and VIP, were searched using a combination of the following search terms: AMI, acute ST-segment elevation myocardial infarction (STEMI), acute non-ST-segment elevation myocardial infarction (NSTEMI), sacubitril/valsartan sodium tablets, and angiotensin receptor enkephalinase inhibitors. The experimental group was given Sacubitril/Valsartan sodium tablets, while the control group was given angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARB). Cochrane Handbook 5.0 risk assessment table were used for quality assessment and bias risk assessment.
    RESULTS: A total of 5 articles were included in the meta-analysis. The total incidence of adverse cardiovascular events in the sacubitril/valsartan group was significantly lower than that in the control group {relative risk (RR) =0.61 [95% confidence interval (CI): 0.46, 0.82], significance testing Z=3.36, and P=0.0008}. The difference between the rehospitalization rate of the sacubitril/valsartan group and control group was statistically significant [RR =0.67 (95% CI: 0.47, 0.95), significance testing Z=2.23, and P=0.03]. The difference in low blood pressure between the sacubitril/valsartan group and the control group was statistically significant [RR =1.28 (95% CI: 1.18, 1.40), significance testing Z=5.58, and P<0.00001]. The difference in left ventricular ejection fraction (LVEF) between the sacubitril/valsartan group and control group was statistically significant [mean difference (MD) =3.09 (95% CI: 1.69, 4.49), significance testing Z=4.33, and P<0.0001].
    CONCLUSIONS: Sacubitril/valsartan was found to inhibit ventricular remodeling after AMI, improve cardiac function, and reduce the incidence of adverse cardiovascular events after myocardial infarction, the rehospitalization rate, and the mortality rate.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号